Phase 2 Start
PBYI: Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
September 30, 2026 · alisertib. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 30, 2026
- Company
- PUMA BIOTECHNOLOGY, INC. (PBYI)
- Drug
- alisertib
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
- Drug
- alisertib
- Indication
- Small Cell Lung Cancer ( SCLC )